when are you finnaly getting your criotherapy"Just watched the Stemson video and it seems like the first product will only be available to a select few i.e. those with money. Does that suggest that the bulk of us will have to wait longer to get access to the technology? say Product 1 is available in 10years and Product 2 available in 15years…"
Kapil Bharti, Ph.D. is a Senior Investigator at the National Eye Institute at the National Institutes of Health. He is a world renowned expert in regenerative medicine, stem cell biology, and developmental biology of the eye. Dr. Bharti is leading the first Phase I/IIa clinical trial in the US using autologous iPSC-derived cells to treat the retinal pigment epithelium in age-related macular degeneration (AMD). His pioneering work in combining iPSC-derived cells together with scaffolds and transferring those solutions into cutting edge, highly controlled and compliant manufacturing processes positions him to guide Stemson’s efforts in similar areas.
George Murphy, M.D. is Co-Director of the Harvard Stem Cell Institute (HSCI) Skin Program, Professor of Pathology at Harvard Medical School, and the Director of the Program in Dermatopathology at the Brigham and Women’s Hospital. He is a Harvard-trained skin pathologist with 40 years of experience as a physician-scientist focused on understanding the pathobiology of human and murine skin. He has authored over 300 peer-reviewed publications and numerous textbooks in the field of skin pathology and has maintained a continuously NIH-funded research lab for over 35 years. Through this Harvard-based research and his role at the HSCI, Dr. Murphy has a major interest in how the genetic and epigenetic factors and related microenvironmental niches participate in complex regenerative phenomena such as scarless wound healing and hair follicle cycling and neogenesis.
If it was any other company you'd be complaining that they just now hired these people so they are far behind, and we'll all be dead before they get anywhere.World-renowned scientists will guide Stemson’s efforts to develop the first iPSC-derived cell therapy to treat hair losswww.businesswire.com
According to the type of talent Stemson is gathering, it looks like they are starting to plan the next phase of their research guys (i.e. clinical trials may be starting to show in the horizon).
If we get a date estimate for that in 2022 it will be great. I'm expecting more clues in their next hires.
They talked about it in the larger presentation at the conference. The are trialing in pigs and focusing on yields and immediate characteristics (hair life cycle, length, health). Sounds like they are dealing with consistency issues right now, and then need to tackle the actual physical attributes of the hair like color and density.Interesting, Hamilton looks like a good guy. However, no information (yet) on how far they actually are, what issues they are facing etc.
Might come in the following parts.
in short, they are not yet sure if their solution will workThey talked about it in the larger presentation at the conference. The are trialing in pigs and focusing on yields and immediate characteristics (hair life cycle, length, health). Sounds like they are dealing with consistency issues right now, and then need to tackle the actual physical attributes of the hair like color and density.
Which other company you speak about? The only full blown company attacking this problem is currently is Stemson. Organ is no more, dNovo is not a proper company yet, and the other dudes are academics publishing papers that will lead to nowhere going after grants, not to mention the borderline scams/money grabsIf it was any other company you'd be complaining that they just now hired these people so they are far behind, and we'll all be dead before they get anywhere.
They are playing very safe and cautiously with their words since around 2 years ago but remember the investors in their last round of investing had in depth access to their research and they decided to invest $15M after seeing it.in short, they are not yet sure if their solution will work